Kogo, Mariko
Fujimoto, Daichi
Hosoya, Kazutaka
Nagata, Kazuma
Nakagawa, Atsushi
Tachikawa, Ryo
Yamashita, Daisuke
Kitamura, Yuka
Imai, Yukihiro
Tomii, Keisuke
Funding for this research was provided by:
AstraZeneca
Article History
Received: 23 October 2019
Accepted: 4 February 2020
First Online: 6 February 2020
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board of Kobe City Medical Centre General Hospital (zh180201). Informed consent was principally obtained with written format except for patients who had been dead or were lost to follow-up. The consent of those patients was waived with approval by our Ethics Committee.
: Not applicable.
: Dr. Fujimoto and Dr. Tomii have received lecture fees from AstraZeneca. Dr. Kitamura is the CEO of N Lab Co., Ltd. and its stockholder. The remaining authors declare no conflict of interest.